By Fineline Cube 
Novo Nordisk A/S (NYSE: NVO) released its first-quarter 2026 financial results on May 6, 2026, reporting net sales of DKK 96,823 million (USD 15.23 billion), representing a 32% increase at constant exchange rates (CER). Reported operating profit grew 65% to DKK 59,618 million (USD 9.38 billion), driven by robust demand across the company’s GLP-1 portfolio and successful commercial execution.
Financial Highlights – Q1 2026
| Metric | Q1 2026 | Growth (CER) | Notes |
|---|---|---|---|
| Net Sales | DKK 96,823M (USD 15.23B) | +32% | Strong performance across diabetes and obesity portfolios |
| Operating Profit | DKK 59,618M (USD 9.38B) | +65% | Significant margin expansion and operational leverage |
| Wegovy Pill Sales | DKK 2,256M (USD 354.87M) | New launch | Impacted by pre-launch pipeline fill with wholesalers and telehealth partners |
Semaglutide Portfolio Performance
Product-Specific Results
- Ozempic (injectable): DKK 27,825 million (USD 4.38 billion) in adjusted sales, down 8% year-over-year, reflecting market dynamics and inventory adjustments
- Wegovy Injectable: DKK 18,235 million (USD 2.87 billion) in adjusted sales, up 12% year-over-year, demonstrating continued strong demand in obesity treatment
- Wegovy Pill: DKK 2,256 million (USD 354.87 million) in Q1 sales following US launch on January 5, 2026
Wegovy Pill Launch Metrics
- Weekly Prescriptions: Exceeded 200,000 for the week ending April 17, 2026
- Q1 2026 Total Prescriptions: Approximately 1.3 million
- Cumulative Prescriptions Since Launch: Over 2 million
- Launch Achievement: Strongest-ever GLP-1 volume launch in US pharmaceutical history
The exceptional prescription growth for Wegovy pill validates the significant unmet need in obesity treatment and demonstrates successful market adoption of the oral GLP-1 formulation.
2026 Outlook & Strategic Guidance
| Metric | Previous Guidance | Revised Guidance (Excluding 340B Provision Reversal) | Direction |
|---|---|---|---|
| Adjusted Sales Growth | Not specified | -4% to -12% at CER | Reflects high base comparisons and inventory normalization |
| Adjusted Operating Profit Growth | Not specified | -4% to -12% at CER | Consistent with sales guidance adjustments |
| Primary Driver | – | Increased expectations for GLP-1 product sales | Upward revision despite percentage range |
The revised guidance reflects increased confidence in GLP-1 product demand, particularly for obesity treatments, while accounting for challenging year-over-year comparisons and supply chain normalization following the exceptional 2025 performance.
Market Impact & Competitive Positioning
- GLP-1 Market Leadership: Novo Nordisk maintains dominant position in the rapidly expanding GLP-1 market, with both injectable and oral formulations achieving strong commercial success
- Obesity Treatment Revolution: The Wegovy pill launch success represents a paradigm shift in obesity management, offering improved patient convenience and adherence compared to injectable alternatives
- Supply Chain Dynamics: Q1 results reflect ongoing efforts to balance inventory levels across the distribution channel while meeting unprecedented demand
- Long-term Growth Trajectory: Despite near-term guidance adjustments, the company’s fundamental growth story remains intact, supported by massive addressable markets in diabetes and obesity
Novo Nordisk’s Q1 performance underscores the company’s ability to execute at scale while navigating complex supply-demand dynamics in one of the pharmaceutical industry’s most competitive therapeutic areas.
Forward‑Looking Statements
This brief contains forward-looking statements regarding financial performance, product sales, and market outlook. Actual results may differ due to risks including supply constraints, competitive pressures, and regulatory changes.-Fineline Info & Tech